| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-17 | Galapagos (Belgium) Janssen Pharmaceutica, a J&J company (USA - NJ) | GLPG1690 | idiopathic pulmonary fibrosis | termination of the licensing agreement |
Inflammatory diseases - Lung diseases - Respiratory diseases | Termination of the agreement |
| 2015-03-17 | Celldex Therapeutics (USA - NJ) Roche (Switzerland) | varlilumab and Tecentriq® (atezolizumab) (MPDL3280A) | renal cell carcinoma (RCC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-03-16 | Genmab (Denmark) ADC Therapeutics (Switzerland) | antibody-drug conjugate (ADC) product combining Genmab\'s HuMax-TAC antibody and ADC Therapeutics\' PBD-based warhead and linker technology | refusal of an option |
Cancer - Oncology | Refusal of an option | |
| 2015-03-16 | MacroGenics (USA - MD) Takeda Pharmaceutical (Japan) | product candidates based ib MacroGenics\' Dual-Affinity Re-Targeting (DART®) proprietary platform | developement commercialisation |
Autoimmune diseases | Milestone | |
| 2015-03-16 | Emergent BioSolutions (USA - MD) GSK (UK) University of Oxford (UK) National Institute of Allergy and Infectious Diseases (NIAID) (USA) | modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) | Ebola fever | production manufacturing |
Infectious diseases | Production agreement |
| 2015-03-16 | Mission Therapeutics (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-16 | Chiasma (USA- MA - Israel) | nomination |
Nomination | |||
| 2015-03-16 | Mission Therapeutics (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-16 | Moderna Therapeutics (USA - MA) | nomination |
Nomination | |||
| 2015-03-15 | Evotec (Germany) Second Genome (USA - CA) | microbiome-mediated diseases | development |
Development agreement | ||
| 2015-03-11 | Cell Medica (UK) The Cell Therapy Catapult (UK) | Cytovir™ CMV | treatment of CMV reactivation episodes in patients following allogeneic haematopoietic stem cell transplant | collaboration |
Infectious diseases - Transplantation - Cancer - Oncology | Collaboration agreement |
| 2015-03-11 | Neovacs (France) | nomination |
Autoimmune diseases | Nomination | ||
| 2015-03-11 | Clinigen (UK) Hospira (USA - IL) | Foscavir® (foscarnet sodium) | HIV/AIDS-related cytomegalovirus infections and herpes | distribution |
Infectious diseases | Distribution agreement |
| 2015-03-11 | Valneva (France- Austria) Merial (France) | EB66® cell line to evaluate the production of additional vaccine candidates | licensing R&D |
Veterinary medicine | Licensing agreement | |
| 2015-03-11 | Valneva (France- Austria) undisclosed European veterinary company | EB66® cell line for the development of viral veterinary vaccines | licensing commercialisation |
Veterinary medicine | Licensing agreement | |
| 2015-03-11 | Valneva (France- Austria) undisclosed European veterinary company | EB66® cell line for the development of viral veterinary vaccines | licensing commercialisation |
Veterinary medicine | Licensing agreement | |
| 2015-03-11 | Ixico (UK) VirtualScopics (USA - NY) Micron (Japan) | clinical trial imaging solutions | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-03-10 | Effimune (France) | nomination |
Nomination | |||
| 2015-03-10 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-10 | Sygnis (Germany) Ozyme (France) | TruePrime™ product family | distribution |
Technology - Services | Distribution agreement |
